secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-041156
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Q3 net loss $5.4M; $36M debt converted to preferred; going concern raised
------------------------------------------------------------------------------

- Net loss of $5.4M ($0.14 diluted EPS) vs $2.4M loss ($0.06) in Q3 2022.
- Cash and equivalents only $0.4M at Sept 30; received $4.4M credit line increase from Juvenescence.
- Converted $36M of debt into Series A/B preferred stock in July, eliminating that liability.
- Signed merger agreement to acquire Serina Therapeutics; G&A surged due to deal costs.
- Company discloses substantial doubt about ability to continue as going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer